Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-assisted therapy for PTSD relapse
NCT01458327Phase 2
Key facts
- Status
- Completed
- Start
- Dec 2010
- Primary completion
- Jun 2014
- Countries
- 1
- Sponsor
- Lykos Therapeutics
- Drugs
- midomafetamine
- Conditions
- post-traumatic stress disorder (PTSD)
01
Overview
Phase 2, open-label trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by Lykos Therapeutics. Primary endpoint: Clinician-Administered PTSD Scale for DSM-IV at 12 months. Started Dec 2010; status: completed.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Adults with chronic PTSD who previously participated in the MP-1 study and experienced a relapse of symptoms.
04
Endpoints
Primary
Clinician-Administered PTSD Scale for DSM-IV
Secondary
Beck Depression Inventory
Beyond the preview
Go deeper on NCT01458327.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01458327.